These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10529885)

  • 21. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
    Jones RN; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):119-26. PubMed ID: 9823536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.
    Ribera A; Jurado A; Ruiz J; Marco F; Del Valle O; Mensa J; Chaves J; Hernández G; Jiménez de Anta MT; Vila J
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):123-8. PubMed ID: 11858908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of sparfloxacin and clinafloxacin against multidrug-resistant enterococci.
    Perri MB; Chow JW; Zervos MJ
    Diagn Microbiol Infect Dis; 1993; 17(2):151-5. PubMed ID: 8243036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Ho DH; Bodey GP
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.
    Cohen MA; Yoder SL; Huband MD; Roland GE; Courtney CL
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2123-7. PubMed ID: 8540728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.
    Milatovic D; Schmitz FJ; Brisse S; Verhoef J; Fluit AC
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1102-7. PubMed ID: 10722524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
    Pascual A A; Joyanes P; Martínez-Martínez L; del Carmen Conejo M; Hernández G; Chaves J; Perea EJ
    Enferm Infecc Microbiol Clin; 2001 Nov; 19(9):432-4. PubMed ID: 11709121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
    Jones RN; Sanchez ML
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
    Tali-Maamar H; Tebbal S; Rahal K
    Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.
    Sader HS; Erwin ME; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):372-81. PubMed ID: 1327789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.